Vident Investment Advisory’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

Vident Investment Advisory’s Portfolio CBPO Stock Details CBPO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-2,312	Closed	-$273K	–	1051
2020 Q4	$273K	Sell	2,312 -10	-0.4%	-$1.16K	0.01%	831
2020 Q3	$258K	Buy	2,322 +119	+5%	+$12.8K	0.01%	793
2020 Q2	$225K	Sell	2,203 -584	-21%	-$62.5K	0.01%	805
2020 Q1	$301K	Sell	2,787 -201	-7%	-$23.1K	0.02%	683
2019 Q4	$348K	Buy	2,988 +878	+42%	+$102K	0.02%	627
2019 Q3	$242K	Buy	+2,110	New	+$210K	0.02%	437

Other funds holding CBPO

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Athos Capital Hong Kong $324M AUM 16.62% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MCP

Maso Capital Partners Hong Kong $60.9M AUM 0.32% 1-Year Est. Return

OMC

Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Vident Investment Advisory's CBPO Position: Q1 2021 in Review

Vident Investment Advisory sold out of China Biologic Products Holdings, Inc. (CBPO) in Q1 2021, closing a stake of 2,312 shares — an estimated $273K sold.

Vident Investment Advisory first reported a position in CBPO in Q3 2019 and held it in 6 quarters. The position peaked at $348K in Q4 2019. 86 funds tracked by Wall St. Rank hold CBPO as of Q1 2021.

Vident Investment Advisory reported no remaining China Biologic Products Holdings, Inc. position as of Q1 2021 after selling out during the quarter.
Vident Investment Advisory sold 2,312 China Biologic Products Holdings, Inc. shares in Q1 2021, an estimated $273K.
Vident Investment Advisory first reported a position in China Biologic Products Holdings, Inc. in Q3 2019 and held it in 6 quarters.
Vident Investment Advisory's China Biologic Products Holdings, Inc. position peaked at $348K in Q4 2019.
86 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q1 2021.

Based on Vident Investment Advisory's 13F filing for Q1 2021, filed 14 May 2021.